Moleculin Q2 2025 cash $7.6M; R&D expense down to $3.6M; MIRACLE trial data readout expected by year-end

Moleculin Biotech, Inc.

Cash and equivalents $7.6M at June 30, 2025, expected to fund operations only into Q4 2025.
R&D expense $3.6M for Q2 2025, down $0.5M from $4.1M in Q2 2024 due to reduced clinical trial activity.
G&A expense flat at $2.1M; no revenue reported for the quarter.
MIRACLE Phase 2B/3 trial expanded to 4 active sites in US, EU, and Georgia; 20+ additional sites expected by end of Q3 2025.
Anticipated unblinded data readout from first 45 subjects in MIRACLE Part A before end of 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.